scholarly journals Time from breast cancer diagnosis to therapeutic surgery and breast cancer prognosis: A population-based cohort study

2018 ◽  
Vol 143 (5) ◽  
pp. 1093-1104 ◽  
Author(s):  
Louise Eriksson ◽  
Jonas Bergh ◽  
Keith Humphreys ◽  
Fredrik Wärnberg ◽  
Sven Törnberg ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Cancer Diagnosis ◽  
Breast Cancer Diagnosis ◽  
Population Based ◽  
Breast Cancer Prognosis ◽  
Cancer Prognosis

scholarly journals Adult children's socioeconomic resources and mothers' survival after a breast cancer diagnosis: a Swedish population-based cohort study

BMJ Open ◽  
2017 ◽  
Vol 7 (3) ◽  
pp. e014968 ◽  
Author(s):  
Hannah L Brooke ◽  
Gunilla Ringbäck Weitoft ◽  
Mats Talbäck ◽  
Maria Feychting ◽  
Rickard Ljung
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Cancer Diagnosis ◽  
Breast Cancer Diagnosis ◽  
Population Based ◽  
Swedish Population ◽  
Socioeconomic Resources

scholarly journals Ten-Year Mortality after a Breast Cancer Diagnosis in Women with Severe Mental Illness: A Danish Population-Based Cohort Study

PLoS ONE ◽  
2016 ◽  
Vol 11 (7) ◽  
pp. e0158013 ◽  
Author(s):  
Anette Riisgaard Ribe ◽  
Tinne Laurberg ◽  
Thomas Munk Laursen ◽  
Morten Charles ◽  
Peter Vedsted ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Mental Illness ◽  
Cohort Study ◽  
Severe Mental Illness ◽  
Cancer Diagnosis ◽  
Breast Cancer Diagnosis ◽  
Population Based ◽  
Danish Population

scholarly journals Dissecting the journey to breast cancer diagnosis in sub‐Saharan Africa: Findings from the multicountry ABC‐DO cohort study

2020 ◽  
Vol 148 (2) ◽  
pp. 340-351 ◽  
Author(s):  
Milena Foerster ◽  
Fiona McKenzie ◽  
Annelle Zietsman ◽  
Moses Galukande ◽  
Angelica Anele ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Cancer Diagnosis ◽  
Breast Cancer Diagnosis ◽  
Sub Saharan Africa ◽  
Sub Saharan

Changes in employment status up to 5 years after breast cancer diagnosis: A prospective cohort study

The Breast ◽  
2019 ◽  
Vol 48 ◽  
pp. 38-44
Author(s):  
Isabel Monteiro ◽  
Samantha Morais ◽  
Ana Rute Costa ◽  
Luisa Lopes-Conceição ◽  
Natália Araújo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Prospective Cohort Study ◽  
Cancer Diagnosis ◽  
Prospective Cohort ◽  
Employment Status ◽  
Breast Cancer Diagnosis

scholarly journals Loss of partner and breast cancer prognosis — a population-based study, Denmark, 1994–2010

2012 ◽  
Vol 106 (9) ◽  
pp. 1560-1563 ◽  
Author(s):  
M H Olsen ◽  
P E Bidstrup ◽  
K Frederiksen ◽  
N H Rod ◽  
M Grønbæk ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Population Based ◽  
Breast Cancer Prognosis ◽  
Cancer Prognosis ◽  
Population Based Study

Time to cancer diagnosis in young women presenting to surgeons with breast-related symptoms: A population-based cohort study.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e13099-e13099
Author(s):  
Tehillah S Menes ◽  
Tal Sella ◽  
Gabriel Chodick
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Young Women ◽  
Cancer Diagnosis ◽  
Breast Imaging ◽  
Breast Biopsy ◽  
Post Partum ◽  
Age Groups ◽  
Population Based ◽  
Diagnosis Of Cancer

e13099 Background: Reports on delay to diagnosis of cancer in young women are based on retrospective studies and conflicting. The purpose of this study was to investigate time to cancer diagnosis in women presenting to a surgeon with breast-related complaints; and particularly, the role of age. Methods: A population-based cohort study including all women aged 18 to 44 presenting to a surgeon with a breast-related complaint between 2005 and 2015 in a large Israeli healthcare plan (N = 157,264). We collected data including demographics, diagnosis codes, breast imaging and biopsies. Breast cancer diagnosis within one year of the visit was ascertained from the national cancer registry. Time to breast imaging and biopsy was compared between the different age groups. Logistic regression analysis was used to determine the association between age and delay to biopsy while adjusting for possible confounders. Results: During the first year after the visit, 45,434 (29%) women had a breast imaging study; 5,767 (3.7%) women had a breast biopsy; and 676 (0.43%) were diagnosed with breast cancer. Overall, time to first breast imaging (mean, 53 days) and biopsy (mean, 68 days) did not differ significantly between the age groups. Non-specific visit codes (other than breast mass) were associated with delays to imaging and biopsy. This was more pronounced in the women ultimately diagnosed with breast cancer. Among women diagnosed with breast cancer, age under 40 (OR 2.3, 95% CI 1.4; 3.9), being post-partum (OR 2.6, 95% CI 1.1; 5.9) and a non-specific visit code (OR-8.3, 95% CI 4.9; 14.2) were associated with delay to biopsy. Conclusions: Symptomatic women with lower a-priori likelihood of breast malignancy (younger age, post-partum, or non-specific visit code) are at a significantly greater risk of delayed diagnosis of cancer. Physicians should be aware of the challenging diagnosis in young women with non-specific symptoms.

Metastatic-free intervals and risk of breast cancer-specific mortality among patients with hormone receptor-positive breast cancer: A population-based analysis from the Surveillance, Epidemiology, and End Results registries.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e13034-e13034
Author(s):  
Gregory Sampang Calip ◽  
Ernest H Law ◽  
Colin Hubbard ◽  
Nadia Azmi Nabulsi ◽  
Alemseged Ayele Asfaw ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Diagnosis ◽  
Breast Cancer Diagnosis ◽  
Population Based ◽  
Breast Cancer Specific Survival ◽  
Cancer Specific Survival ◽  
Breast Cancer Specific Mortality ◽  
Specific Mortality ◽  
Cancer Specific Mortality ◽  
Positive Breast Cancer

e13034 Background: Patients successfully treated for hormone receptor (HR)-positive early breast cancer remain at risk of recurrence and metastatic disease even after extended periods of disease-free years. Whether prolonged metastatic-free intervals ultimately confer a benefit to breast cancer-specific survival is not well understood. This study aimed to investigate metastatic-free intervals and risk of breast cancer-specific mortality among patients with HR-positive breast cancer after adjuvant therapy. Methods: We conducted a retrospective cohort study of women aged 18 years and older diagnosed with recurrent metastatic HR-positive breast cancer between 1990 and 2016 in the Surveillance, Epidemiology, and End Results registries. Patients with longitudinal information on primary stage I-III HR-positive breast cancer through the occurrence of metastatic disease and survival were included. Risks of breast cancer-specific mortality associated with metastatic-free intervals (defined as time from primary breast cancer diagnosis to metastasis) of ≥5 years compared to < 5 years were estimated. Fine and Gray competing risks regression models were used to calculate subdistribution hazard ratios (SHR) and 95% confidence intervals (CI). Results: Among 1,057 women with HR-positive breast cancer with a median age of 54 years at primary breast cancer diagnosis and 62 years at metastatic progression, 65% of women had a metastatic-free disease interval ≥5 years, whereas 35% had an interval of < 5 years. Overall, patients with metastatic-free intervals < 5 years had a five-year breast cancer-specific survival rate of 31% compared to 52% in women with intervals of ≥5 years. In multivariable analyses adjusted for age, race, diagnosis year, grade, treatment and sites of metastasis, patients with intervals of ≥5 years had decreased risk of breast cancer-specific mortality (SHR = 0.72, 95% CI 0.58-0.89, P = 0.002) compared to women with metastatic-free intervals of < 5 years. Conclusions: In this population-based study, rates of cancer-specific mortality among patients who experienced metastatic recurrence of HR-positive breast cancer were lower in women with metastatic-free intervals of 5 years or more. The results of this study may inform patient-clinician discussions surrounding prognosis and treatment selection among HR-positive patients.

Sign in / Sign up

Export Citation Format

Share Document